产品
编 号：F742864
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1174900-84-5
产品详情
生物活性：
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion.
体外研究：
Ficlatuzumab (20 μg/mL; 24 h) effectively decreases tumor-associated fibroblast (TAF)-conditioned media-facilitated HNSCC migration and invasion.Ficlatuzumab (20 μg/mL; 24 h) effectively mitigates TAF-facilitated epithelial-tomesenchymal transition (EMT), Vimentin expression in HNSCC cells.Ficlatuzumab (20 μg/mL; 72 h) reduces proliferation induced by TAF-secreted hepatocyte growth factor (HGF) in HNSCC cells.Ficlatuzumab (20 μg/mL; 16 h) reduces the phosphorylation of c-Met and p44/42 MAPK in HNSCC cells compared with cells treated with recombinant HGF alone.
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion.
体外研究：
Ficlatuzumab (20 μg/mL; 24 h) effectively decreases tumor-associated fibroblast (TAF)-conditioned media-facilitated HNSCC migration and invasion.Ficlatuzumab (20 μg/mL; 24 h) effectively mitigates TAF-facilitated epithelial-tomesenchymal transition (EMT), Vimentin expression in HNSCC cells.Ficlatuzumab (20 μg/mL; 72 h) reduces proliferation induced by TAF-secreted hepatocyte growth factor (HGF) in HNSCC cells.Ficlatuzumab (20 μg/mL; 16 h) reduces the phosphorylation of c-Met and p44/42 MAPK in HNSCC cells compared with cells treated with recombinant HGF alone.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备